Oral treatment with Galafold (migalastat) helped keep kidney and heart function largely stable over years of follow-up in adults with Fabry disease, according to a real-world U.K. study. The therapy also significantly reduced blood levels of lyso-Gb3, a disease biomarker, in both people starting treatment for the first…